Category Archives: Florida Stem Cells

MIAMI, May 12, 2022 (GLOBE NEWSWIRE) -- American Academy of Stem Cell Physicians is proud to welcome acclaimed Opthamalogist Dr. Scheffer Tseng as Guest Speaker.

American Academy of Stem Cell Physicians will host expert speakers from across the country lecturing on the recent innovations in Stem Cell research on June 17-19, 2022 in Miami.

The American Academy of Stem Cells Physicians is excited to be back at The Hyatt Hotel, this June 17-19, 2022. The Academy is proud to confirm Dr. Scheffer Tseng, one of the most well known experts in the Regenerative field.

"The Academy is proud to offer State-of-the-art Regenerative workshops this June, they will be lead by experts with over 100 years of combined experience," said Dr. Sunny Kim, President of the AASCP.

Dr. Scheffer Tseng, the guest speaker for AASCP in June on June 18, is a pioneer and practicing ophthalmologist in Miami Florida. Dr. Tseng is a founder of BIO-TISSUE. Dr. Steng said; "I know how important it is to maintain the highest standards in clinical care for both my practice and my patients. And as a research scientist, I know how critical quality data is to the development of strategies and therapies that can truly impact patient care and improve clinical outcomes. For more than 30 years, I have been dedicated to making a positive difference in the lives of my patients."

The American Academy of Stem Cell Physicians invites you to learn more about how Bio-Tissue can help heal patients with a number of ocular surface and lid margin diseases. Dr. Tsenf went on to add, said, "I am looking forward to discussing all the new advancements in the Regenerative field for 2022."

The spokesman for the AASCP, Dr. AJFarshchian,said earlier: "The American Academy of Stem Cell Physicians is a group of physicians, scientists and researchers who collectively represent the most authoritativenon-federal group advocating for guidelines and education on stem cell therapy and regenerative medicine. The AASCP is involved directly with other authorities within the field and seeks only to bring knowledge and awareness for the ever-growing regenerative medicine industry."

AASCP is hosting their medical conference in Miami on June 17-19, 2022. The conference is taking place at the downtown MiamiHyatt Regency, located at 400 SE 2nd Ave., Miami, FL 33131.Becauseof limited seating, we encourage everyone to please RSVP atwww.aascp.net andto register. Registrations are going fast, please register today.

The American Academy of Stem Cell Physicians (AASCP) is an organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatmentand prevention of disease related to or occurring within the human body. Secondarily, the AASCP aims to serve as an educational resource for physicians, scientistsand the public in diseases that can be caused by physiological dysfunction that areameliorableto medical treatment.

For further information, please contact WilsonDemenessez or Luana Ingrid at AASCP 305-891-4686, and you can also visit us at http://www.aascp.net.

Related Images

Image 1: American Academy of Stem Cell Physcians lecture

lecture

This content was issued through the press release distribution service at Newswire.com.

Read more:
American Academy of Stem Cell Physicians is Proud to Add to the Speaker Roster, Dr. Scheffer Tseng, Acclaimed Opthamologist and Founder of Bio-Tissue...

When Mark Bryant began suffering with a bad back, he thought a few strong painkillers would sort it out. However, the pain got progressively worse to the point where he had to call for an ambulance.

A series of blood tests were carried out in hospital which discovered, to the dad-of-two's complete shock, that he was living with a rare form of blood cancer. "In that moment the world stopped," he said. "The thing that I was initially stressing out just didn't matter anymore. I was immediately into problem-solving mode."

Mark, from the seaside resort of Rhos on Sea, Conwy, said the moment he told his wife Fiona about his cancer remains "very raw". Just two years earlier, his own mother Elizabeth had died from the disease which he admitted allowed him to prepare for what was to come.

Read more:'We're seeing mums whose cancer has become untreatable because the NHS backlog is too big'

Recalling his diagnosis in June 2015, he added: "The reason why I wasn't in 'oh s***' mode at the time was because I was on morphine to numb the pain, and steroids which got me in remission. I then had two months of chemotherapy, which was very strong, and full-body radiotherapy."

Mark, who at this point was given just a 50% chance of survival, explained that the pain in his back was so severe due to his bone marrow being "overloaded with bad cells". He was then given a stem cell transplant from his brother Adam, but he relapsed in April 2016. "I have since discovered that my prognosis was considered terminal, with a life expectancy of six months, and the additional treatment I was offered was given with palliative intent," Mark added.

However, rather than accepting his fate Mark embarked on his own "healing journey" by trying to rebuild his immune system using immunotherapy, functional medicine and lifestyle medicine. In 2017 he travelled to Florida to receive his first round of privately-funded immunotherapy treatment which aimed to rebuild his "natural killer cell function".

He then decided to return for three more rounds, with each block lasting approximately six weeks. However he hasn't been back since 2018 due to increasing financial pressures. Most recent tests have shown that the cancer is still present in him. "I wish I could say I was fully healed but, unfortunately, I can't. It's like sleeping with a rattlesnake not knowing when it might strike again," he added.

But almost seven years on from his initial leukaemia diagnosis, Mark continues to defy doctors' expectations. He has now created the 'Terminal to Triathlon' project, has hosted his own podcasts on the subject and plans to complete the Ireland Ironman in August 2022 in 13 hours or less.

"I am approaching my healing journey and the ironman like a professional athlete is training for their gold medal in the Olympics. The only difference is my gold medal is my health and helping re-write the script for mainstream medicine, accelerating the switch from a reactive to proactive healthcare system," he said.

Mark's aim is to raise 500,000 on his GoFundMe page, with 60% of it going directly to help other cancer patients access complementary, alternative and rehabilitation services and programmes. Another 20% will go towards the running of the 'Terminal to Triathlon' project and the final 20% towards his continued research and treatment - which could include returning to Florida for further immunotherapy.

"The money is a drop in the ocean compared to the 5bn cancer costs the NHS in the UK. Whilst I fully support everything modern medicine can offer, unfortunately there are gaping holes in the system to properly support true healing," he said.

Continued here:
'Doctors gave me six months to live in 2016 but I continue to defy every expectation' - Wales Online

The new non-invasive treatment involves the provision of a spacious, pressurized oxygen chamber that delivers pure oxygen, stimulating the release of stem cells that regenerate blood vessels and tissues

March 23, 2022 A new oxygen healing therapy is now available at one of the top wellness and drug rehab centers in Florida. House of Freedom is dedicated to providing individualized care in a safe and compassionate environment. They ensure patients maintain the highest level of physical, psychological, and spiritual well-being with the latest in healing and recovery technology.

Oxygen Healing is a new therapy shown to be effective in the treatment of multiple disorders such as migraines, PTSD, ADHD, autoimmune disease, depression, and anxiety. Our bodies need adequate oxygen to function, but when any part is injured, it requires even more oxygen to repair and survive. The process involves exposing the body to pure oxygen at a pressure that is greater than that found in our environment. The oxygen then stimulates the release of substances like growth factors and stem cells, which can then regenerate blood vessels and create new tissue. At the same time, it can significantly reduce swelling and inflammation and relieve the pain associated with tissue damage. Thats why this breakthrough treatment also speeds up recovery in those with an alcohol or drug addiction.

While the Orlando-based substance abuse center primarily attends to patients struggling with addiction, it has however revealed that it will extend its oxygen healing therapy to accommodate patients suffering from all kinds of illnesses and injuries, including those not related to drug abuse or alcohol addiction.

Aside from the new hyperbaric oxygen healing therapy, the substance abuse center provides a combination of brain imaging studies (brain SPECT), neurotransmitter tests, DNA tests, nutritional plans, physical conditioning, blood tests, and sleep quality studies.

In addition to outpacing other fellow clinics in the space with its impressive integration of top technologically driven solutions, the leading substance abuse rehab in Kissimmee is one of the first clinics in the east coast to offer this type of hyperbaric oxygen therapy.

Were proud to be one of the first to introduce Oxygen Healing to our community. We believe this further reaffirms our commitment to providing only the best treatment solutions and sets the pace for other centers like us to follow.

House of Freedom has over 20 years of experience offering a multi-faceted therapeutic approach to addiction ranging from prevention to intervention and aftercare for individuals suffering from substance abuse.

The professional treatment center is run by an experienced team of doctors, technicians, therapists, fitness and nutrition coaches, and even former addicts with real success stories who possess a first-hand understanding of the challenging road to recovery and are personally vested in the continued progress of all their patients. Tambien cuentan con personal que habla Espaol en este Centro de Rehabilitacin de Drogas.

Anyone seeking more information regarding House of Freedom can reach out to the center via the contact info below.

Media ContactCompany Name: House of FreedomContact Person: Orlando Vargas, Director of Research DevelopmentEmail: Send EmailAddress:2311 North Orange Blossom Trail City: KissimmeeState: FL 34744Country: United StatesWebsite: https://houseoffreedom.com/

Here is the original post:
Revolutionary Oxygen Healing Therapy Now Available in Florida - Digital Journal

The Global Mesenchymal Stem Cells Market Report by QY Reports is a meticulously undertaken study. Experts with proven credentials and a high standing within the research fraternity have presented an in-depth analysis of the subject matter, bringing to bear their unparalleled domain knowledge and vast research experience. They offer some penetrating insights into the complex world of Mesenchymal Stem Cells Market Industry. Their sweeping overview, comprehensive analyses, precise definitions, clear classifications, and expert opinions on applications, make this report nothing short of brilliant in its presentation and style.

Key Players Influencing the Mesenchymal Stem Cells Market:

Lonza

Thermo Fisher

Bio-Techne

ATCC

MilliporeSigma

PromoCell GmbH

Genlantis

Celprogen

Cell Applications

Cyagen Biosciences

Axol Bioscience

Download PDF Sample Copy of this Report: https://www.qyreports.com/request-sample/?report-id=321253

The documented report aims to offer an organized and methodical strategy for important aspects that have affected the market in recent years and future market opportunities that companies can trust. It gives readers clear market research for better judgment and better decision making on whether or not to invest. The report provides an analysis and overview of the future dynamics with an in-depth analysis of the most important players that are likely to contribute to the growth of the global Mesenchymal Stem Cells market during the forecast period.

The market report also provides a correct assessment of the company strategies and business models that companies implement to stay in the market and lead. Some of the most important steps companies are taking are mergers and acquisitions, partnerships and collaborations to expand their regional and global reach. In addition, the players are also launching a new range of products to enrich their portfolio by using the latest technology and implementing them in their company.

The report is updated with the impact of the currently unfoldingCOVID-19pandemic. The pandemic has dynamically affected the key segments of the market and has changed the growth pattern and demands in the Mesenchymal Stem Cells Market. The report covers extensive analysis of these changes and provides an accurate forecast estimation of the market growth after the impact of the pandemic.

Mesenchymal Stem Cells Market Segmentation:

The report has classified the market into segments including product type, and application. Every segment is evaluated based on share and growth rate. Besides, the analysts have studied the potential regions that may prove rewarding for the manufacturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall industry.

Ask for Discount on this Premium Report: https://www.qyreports.com/ask-for-discount/?report-id=321253

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global Mesenchymal Stem Cells market based on the type and application. It also provides market size and forecast till 2028 for overall Mesenchymal Stem Cells market with respect to five major regions, namely; North America, Europe, Asia-Pacific, Middle East and Africa and South America. The market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast globally along with the current trends and opportunities prevailing in the region.

Why the Mesenchymal Stem Cells Market Report is Beneficial?

If You Have Any Query/Inquiry, Ask Our Expert: https://www.qyreports.com/enquiry-before-buying/?report-id=321253

Major Highlights of the Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team, who will ensure that you get a report that suits your needs.

Seeking to initiate a fruitful business relationship with you!

About Us

We at QYReports, a leading market research report publisher cater to more than 4,000 prestigious clients worldwide meeting their customized research requirements in terms of market data size and its application. Our list of customers include renouned Chinese companies multinational companies, SMEs and private equity firms. our business study covers a market size of over 30 industries offering you accurate, in depth and reliable market insight, industry analysis and structure. QYReports specialize in forecasts needed for investing in an and execution of a new project globally and in Chinese markets.

Contact Us:

Name: Jones John

Contact number: +1-510-560-6005

204, ProfessionalCenter,

7950 NW 53rd Street, Miami, Florida 33166

sales@qyreports.com

http://www.qyreports.com

Read the rest here:
Global Mesenchymal Stem Cells Market Analysis, Opportunities, Trend and Forecast To 2029 Discovery Sports Media - Discovery Sports Media

education spotlightAs we enter 2022, below are some Florida Tech research highlights from 2021. (Florida Tech image)

BREVARD COUNTY MELBOURNE, FLORIDA As we enter 2022, here are some Florida Tech research highlights from 2021.

At the Orbital Robotic Interaction, On-orbit servicing, and Navigation (ORION) lab, multiple of space-related research projects are underway, led by Markus Wilde, aerospace, physics, and space sciences associate professor.

One of the current projects is a parabolic flight experiment funded by NASA, called the Autonomous Multi-Cycle Farming System.

The team, consisting of Wilde, mechanical and civil engineering assistant professor Hamidreza Najafi, and aerospace, mechanical engineering, and computer science student researchers, took a 2020 Senior Design project, a modified 3D printer to implant and nurture plant seeds into water-filled feed trays in space, and are turning it into an experiment for a parabolic flight.

Brian Kish, an aerospace, physics, and space sciences associate professor is supporting the project with flight testing.

According to Wilde, the feed trays have been successful in growing plants and the team plans to fly in late November or early December this year.

What we are going to show with that parabolic flight is that the planting mechanism works fine in microgravity and that the system is able to function through changes from zero gravity to 2Gs, Wilde said.

The cool thing is that these parabolic flights also provide Martian gravity and moon gravity, so were going to be able to show the system works on orbit, on the moon, and on Mars.

As the focus on climate change and electric transportation increases, the first-in-the-nation acquisition for Florida Tech will allow for hands-on learning and important research on a new and timely aspect of aviation.

In August, the school became the only American university to own and fly an electric plane. The Velis Electro, a light aircraft from the Slovenian company Pipistrel, was introduced last year.

The first electric-powered airplane certified in Europe, it has a maximum speed of 181 km/h (113 mph, 98 knots), zero emissions, an engine with a noise level of 60 decibels (quieter than the single-engine Cessna 172 which is 85 decibels) and a body made of composite materials. The plane costs $190,000.

The two-seater has not been flown in the United States until now. It is awaiting U.S. certification, so Florida Tech is flying it under the experimental category.

Florida Tech alumnus and former associate dean Isaac Silver was the pilot for the inaugural flight. He flew for 22 minutes, using about a third of the aircrafts battery capacity and creating an operating cost of only $1.03.

The plan will give students the opportunity for experiential research with cutting-edge technology, providing a research value added to their educational experience.

While we can teach students flight test techniques using older aircraft, having them test an airplane with the latest technology prepares them for contemporary designs, said Brian Kish, Flight Test Engineering program chair and aerospace associate professor. For more, click here.

As reefs face threats from climate change, Florida Tech is exploring 3D printing to potentially help sustain this critical but threatened ocean resource.

Ocean engineering and marine sciences professor Stephen Wood and research students John Carroll, Sydney Goodman, Gabija Karosas, Alexa Langley, August Neier, and Katherine Tyson are proposing to use a 3D printer to make coral structures that would then be placed upon large mounds of concrete in the ocean.

The goal is to design a production method in which creating artificial coral reefs is accessible and affordable, and using 3D printing would decrease the time to produce artificial corals.

The team is working to build a printer that is much larger than common printers on the market, which will allow them to print life-size corals.

To reach their goals, the team assembled a smaller 3D printer to familiarize themselves with the mechanisms and construction of 3D printing.

They then designed a full-scale 3D printer to print in ceramic, though there is a future option to print in concrete.

Mixing engineering and coral biology, the researchers looked at different 3D-printer parts and filament materials as they would relate to various corals and designs, and they also considered how the printed products would react in the ocean environment.

The team also used a sample printer to print small models of corals, which represent the final print concept.

While the printed corals may not look identical to the real thing, they will be designed with an important goal in mind: facilitate coral growth.

We may print out the base structure of the coral, like an Elkhorn coral, we could print a good majority of that, so when the little polyps adhere, they could grow off of that, Wood said. For more, click here.

Facial recognition and analysis, and the machine learning techniques behind them, have many applications, from affirming identity documents to unlocking mobile phones.

Now, this technology may have the power to help doctors better understand and diagnose neurodegenerative diseases.

Diego Guarn, assistant professor in the biomedical engineering program, has been working on using facial recognition and analysis and machine learning algorithms to evaluate the effects of different neurodegenerative and motor disorders in speech production and facial movements.

The overall goal of Guarns research is to use facial recognition techniques to analyze if patients have neurodegenerative or motor disorders, such as Bells palsy, Parkinsons disease, and ALS.

Using this new technology would allow doctors to provide more effective care to individuals who are developing these diseases, as well as to track disease progression and provide a baseline to see if those with the disease are improving with treatment.

Using an artificial neural network to find a specific location on the face, Guarn then uses the recognition technology to track how the person moves their face.

His experiments are currently performed in well-controlled environments, such as a room with a good camera, low noise, and proper illumination. Guarns next work will involve testing these approaches to detect neurodegenerative diseases in home environments during a video call.

The patients are going to perform certain exercises in front of the camera, such as opening their mouth and saying some sentences, he said.

The computer is going to track how the patient moves their mouth and face, and then were going to have an idea of if that movement belongs to a healthy individual in their age group or if that movement belongs to a person with a specific disease. For more, click here.

There is an urgent need to develop sustainable agricultural practices and ensure food security at a much higher level than has ever been attempted or required.

According to a study conducted by Bisk College of Business assistant professor Darrell Burrell and others, this leap might only be possible with the rapid development and application of cutting-edge technologies, including artificial intelligence (AI).

Burrell, along with colleagues from Grand Canyon University, Temple University, and Illinois Institute of Technology, published Exploring technological management innovations that include artificial intelligence and other innovations in global food production, in the International Journal of Society Systems Science last year.

The research offered new data on technological innovations that may help overcome agricultural concerns for meeting a process improvement initiative.

The study analyzed technologies being used to increase food production and included insights from those in the industry.

The research found there were several AI-related systems that are used in farming, ranging from drones surveying the crops to solar panels and sunset-triggered irrigation to motion sensor technology that serves as a digital scarecrow by scaring birds away from crops with a simulated human yell.

The paper even looked at robots picking crops.

The things that Ive seen in my research are the ability to capitalize on technologies that were maybe intended for one purpose but are now being used for another, Burrell said.

The ability to use drones to survey your farm actually makes things more efficient. Instead of me having maybe five people inspecting my farm, I could sit in my farmhouse and use this drone to inspect and review what is going on. For more, click here.

Our brain is made of millions of cells called neurons. Neurons send electrical messages to talk to each other in patterns of vertical electric activity called oscillations.

By inducing them first, then finding the amplitude of the specific brain waves improved during memory, ultimately memory performance itself is boosted. Once introduced, what if a person can boost the speed of these oscillations to improve memory? A university study in a journal for adolescents may show we can do just that.

Psychology assistant professor Rick Addante and clinical psychology doctoral student Mairy Yousif, along with researchers from California State University, San Bernardino, looked at the brain-boosting potential in the research paper, Boosting Brain Waves Improves Memory.

The paper was published in the November 2021 edition of Frontiers for Young Minds, an open-access scientific journal written by scientists and reviewed by a board of kids, teens, and expert scientists.

As the largest impact journal in the entire Frontiers system, this allows for more (and younger) eyes to look at new scientific research that is not often seen by the masses.

The original empirical discovery was published as a technical report, but this version was specially developed and written for accessibility to public STEM audiences.

[Cognitive neuroscience is] a pretty niche field and we dont get a lot of exposure and readership on what the discoveries are, but through this journal that theyve developed, they can get millions of downloads per month of individual articles because its free, its open access to kids all around the world, Addante said.

The team analyzed if memory could improve by stimulating the brain using flashes of lights and sounds that caused the brainwaves to be in sync.

People received rhythmic brain stimulation in special goggles and heard auditory beeps in headphones. This process, known as entrainment, trains the brain to be in sync at a specific wave pattern called theta.

People whose brains were trained to be in theta showed improved memory compared to people receiving random stimulation.

The team found that entrainment can safely manipulate brain waves to improve peoples memory, which opens the possibility of using devices like the ones researched for helping people who suffer from memory disorders. For more, click here.

CLICK HERE FOR BREVARD COUNTY NEWS

Read more from the original source:
EDUCATION SPOTLIGHT: Florida Tech Highlights Work Done During 2021 as We Enter the New Year - SpaceCoastDaily.com

A 51-year-old man presented with worsening fatigue on exertion and pallor, with an ECOG performance score of 1. He eventually received a diagnosis of stage II standard-risk multiple myeloma after testing and examination.

During a Targeted Oncology Case-Based Roundtable event, Kenneth Shain, MD, PhD, of Morsani College of Medicine at the University of South Florida in Tampa, FL, discussed a 51-year-old patients with newly-diagnosed multiple myeloma with a group of peers.

MANCHANDANI: For most of my patients I tell them theyre OK. [Although myeloma is incurable], depending upon if its stage II disease, the chances of their survival are good with the newer treatment options out there. Considering the young age [of this patient] andgood performance status, he will be a candidate for transplant.

KREM: I take people through the ISS and I explain the general life span estimates associated with [each stage]. I also explain that any patients prognosis can be different based upon the responsiveness of their disease and their willingness, and ability, to undergo transplant. While cytogenetics and other prognostic features such as ISSR give some prediction of how people will do, theyre not absolute predictors. Ive had people with stage III disease do wonderfully and people with stage I be almost refractory to treatment.

I always let them know theres some wiggle room in that, but I give them a general expectation that this is thought to be incurable, but we can manage it for a fairly good number of years with all the different therapies we have out there. I also explain that with transplant, we probably get the best duration of survival but we dont knowfor sure [how long that duration will last] and that Ive had some patients go 10 to 15 years with multiple myeloma. I also tell people to try to hang in there if they can, because the longer they hang in there, the newer agents well have to manage their disease down the road. But I leave a little bit of a glimmer of hope open while also telling them they have a chronic disease and [that] theyre likely to be seeing me or [some] of my colleagues for a prolonged period.

SHAIN: Does anybody else have a different way of approaching [their patient] or [an opinion] that would be a little counter to [that line of thinking]? Or are we all pretty much in agreement?

ATRASH: In terms of how I run that discussion with my patients, its one of the most challenging discussions, especially for patients with multiple myeloma. Since [2014 there have been a] lot of new drugs added to the market, and if you look at the overall survival for these patients its getting better and better. Still, its very difficult to predict survival for patients based on the ISSR, [although] its a helpful tool in the discussions about transplant or maintenance and [their long-term treatment plan]. But survival is changing [because of] newly approved drugs, so I try to avoid any discussions about survival, especially when we know that some data are showing numbers that are completely different from myeloma centers. It seems like multiple myeloma is a disease [from which], if you have access to novel treatments, you get better; but it depends, and there are a lot of variables there. I think in myeloma centers, where the research is ongoing, the survival almost doubled. It means the researched new drugs that are coming to the market are probably more powerful than the drugs that we have right now.

SHAIN: You kind of have to use the ISSR [scores] as guidelines or guide markersbut they are the only ways of categorizing patients. We all know their [ISSR scores] dont quite behave, and we also know that they were really based on very specific high-risk cytogenetic features. There are ones that have not been incorporated and there are thingsevolving along the way. Not all patients with myeloma read the book, [so to speak,] and their disease doesnt behave the way its supposed to or they cant tolerate drugs. [Getting patients] on the right path of therapy is probably the most important thing. Balancing that hope and that reality. I think hope is something they need to hold onto, because theres a lot more hope than theres ever been in the past with this disease. But it also leads into what is the most appropriate way to take care of these patientsa lot [of which concerns] this transplant-eligible case. I dont really [perform] transplants [in] individuals, but I have them all [receive] transplants when possible.

KREM: I say transplant eligibility is there until they prove theyre not eligible, so for patients 75 or younger, but Ive [performed transplants in] people up to [age] 76 or 77 if they look right, and they have to have a caregiver. They have to have adequate cardiac and pulmonary function and they have to demonstrate good treatment [adherence], and they cant have an active infection. Of course, their disease has to show some glimmer of chemotherapy response and you dont want to put someone through high-dose [treatment] if all the indications are theyre not going to get any mileage out of that. I would say that this patient has painted a picture of someone whos purely a transplant candidate butwho presents another difficult situation because hes not someone whos going to reach his expected life expectancy with standard therapies.

SHAIN: Does anybody else have a different opinion about transplant or a similar [one]? How do you think about that and when do you introduce it?

EPNER: I sell it as, I would take care of them at all phases of their care and oversee them rather than having to refer them and then having communication with the transplanting doctor.There are several FDA-approved drugs, such as ibrutinib [Imbruvica] andpost transplant, cyclophosphamide [Cytoxan]. There are a lot of ways that we can probably make graft-vs-host disease more livable as opposed to giving them another disease thats worse than the disease they had to begin with. I will have that discussion with people and tell them they would have to do it under a clinical trial and have to go [to a bigger cancer center].

KREM: I think that also brings up the question of how you define young patients and what is young.Some people might say that young [patients] are patients under 65 years old, but I think theres especially young. Whos really young? Because there are some patients who are in their 50s or their 40s and you might want to bring that discussion up with them. Maybe you get them under control with the first [autologous stem cell transplant] and then you have a plan ready at first relapse of how youre going to handle them. I think for someone in their 40s or early 50s, just the standard cells for 2 transplants arent quite enough [for] planning and thinking about the future.

SHAIN: Allogeneic transplant is one of the things that I discuss much less than I did even 5 or 10 years ago. Thats because of therapies that exist. I have people that have [had] allogeneic transplant and theyve done very well, and I have people who have [had] allogeneic transplant and theyve done very poorly. So, its still a question we have to think about.

SHAIN: VRd [bortezomib (Velcade) plus lenalidomide (Revlimid) and dexamethasone] is the standard of care and has been the standard of care for a long time for [patients who are] transplant eligible.1 It looks like everybody recognizes that CyBorD or [daratumumab (Darzalex) plus] VRd is only effective in patients with renal failure and probably shouldnt be a standard of care based on data we have. No KRd [carfilzomib (Kyprolis) plus lenalidomide (Revlimid) and dexamethasone] individuals, thats reasonable, though there are some questions there. I would tell you that today Im a DRVd [daratumumab, lenalidomide, bortezomib, and dexamethasone] guy, and I think [that with] the data [from the GRIFFIN trial (NCT02874742)], and if you marry in a little bit of Cassiopeia [NCT02541383 data], theres really strong evidence for 4 drugs to drive the disease down.

KREM: I think its an important point to make that bortezomib is not in all the publications, but there are more and more data starting to come out about the efficacy of the bortezomib dosing schedule.

SHAIN: We know our question is really triplet vs quadruplet. So how are we doing bortezomib in those dosing regimens and what do you think about it?

KREM: With the bortezomib, [data have] suggested that giving bortezomib twice a week for more than a cycle really beats people up. Whether you do it subcutaneously or intravenously, 1.3 mg/m2 in that dose density of cycles 1, 4, 8, and 11 really isnt tolerated long.

PAUL: I also exclusively use weekly bortezomib with the GRIFFIN regimen. Ive had patients [whom] Ive converted to a 28-day regimen as opposed to the 21-day regimen thats currently being evaluated. If I do the 28-day regimen, I do not do weekly daratumumab for cycles 1 through 3, which is what is being evaluated for the current trial. I do that to minimize toxicities and also for patient convenience. We have a lot of patients who come from far away to get their treatments and its challenging to make them come twice a week or even weekly for 12 weeks in a row.

SHAIN: I [also think weekly treatment] makes life a lot easier. Whether it be 1 or 2 cycles of twice weekly [treatment] is probably not terrible, but Ive moved away from it. I was a stickler for a long time to get some dose-dense bortezomib in the beginning, but I think its an important point that we all really understand that keeping people on the drug is more important than getting them a little bit of dose-dense [drug] to begin with.

EPNER: I had a patient with [a recent] myeloma [diagnosis], a couple [of them], in the COVID-19 era, before the vaccines were available. I was concerned about bringing them into the infusion room and exposing them to the risk. What I did was start them on ixazomib [Ninlaro] until they could get vaccinated and then I switched it over to bortezomib. Now, I sent them for their transplants to Emory [Transplant Center] and talked to some of the members of the team there, and they didnt have a very strong opinion about the use of ixazomib in terms of its efficacy.

SHAIN: Ixazomib is a good drug but its not bortezomib. Its a very good drug for the right person who doesnt want to come in or who cant come in. Ive seen it work outstandingly for patients in combination. Ive used it multiple times, but it is not what I walk in thinking about and its not something I often pick forpatients [with a new diagnosis].

KREM: On the plus side for ixazomib, it has great tolerability. I have seen much [fewer] adverse eventscompared with the other therapies. I would politely say that Im not sure how good the single agent or the doublet efficacy is for that drug. It does reasonably well in combination with other agents, but I think it does have a specialized setting, and as you said, Dr Shain, I dont think it replaces bortezomib.

ATRASH: I dont think I had much luck with ixazomib 4 mg, but yes, some patients do get a lot of benefits from ixazomib. In [a phase 1/2 study (NCT01217957)] that showed us that [the] high-risk population did get benefits from ixazomib, all the new data are [indicating that] perhaps ixazomib is not as effective as bortezomib.2 At the beginning of COVID-19at the very beginningI did a similar approach where I tried to avoid infusion center visits, but later we figured out that perhaps going very aggressive, despite COVID-19, is the best approach.

References

1. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936-945. doi:10.1182/blood.2020005288

2. Kumar SK, Berdeja JG, Niesvizky R, et al. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 2019;33(7):1736-1746. doi:10.1038/s41375-019-0384-1

View original post here:
Roundtable Discussion: Shain Looks at the Role of Transplant Eligibility in Patients With Newly Diagnosed Multiple Myeloma - Targeted Oncology

image:Jessica Bush, a graduate student at the Skaggs Graduate School for Chemical Biology at Scripps Research in Jupiter, Florida, goes over her experiments with Chemistry Professor Matthew Disney, PhD, and Research Associate Haruo Aikawa, PhD. The team published a study in Science Translational Medicine that describes a way of targeting inherited ALS and frontotemporal dementia. view more

Credit: Scott Wiseman for Scripps Research

JUPITER, FL One of the most commonly inherited forms of ALS and frontotemporal dementia is referred to as C9 ALS/FTD, so named for the repeated section of DNA on chromosome 9 that causes it. A collaboration led by scientists at Scripps Research in Florida has successfully treated the genetic disease in mice, with a potential drug molecule engineered in the lab of chemist Matthew Disney, PhD. The compound works in a new way, by directing the cells own immune machinery to degrade and eliminate the disease-causing RNA.

The teams study is published Wednesday in the journal Science Translational Medicine. Collaborators include Leonard Petrucelli, PhD, of the Mayo Clinic in Jacksonville, and Jeffrey Rothstein, MD, PhD, of Johns Hopkins University in Baltimore.

Also known as Lou Gehrigs disease, ALS causes progressive loss of motor neurons, the elongated nerve cells that connect muscles to the central nervous system. As motor neurons die, paralysis, muscle loss, swallowing and eventually, breathing difficulties develop, leading ultimately to death. Scientists are learning that ALS has multiple causes, some of them sporadic, and some inherited or familial.

Frontotemporal dementia similarly has both familial and sporadic causes. It involves progressive damage to neurons in the brains frontal and temporal lobes. Symptoms may include difficulty walking or odd behavioral and emotional states. Like ALS, there is no cure for frontotemporal dementia.

One disease, many symptoms

While people with FTD appear outwardly to have a completely different illness than people with ALS, those whose condition is caused by the C9 genetic repeat have the same disease. Manifestations differ according to cell types affected. The more times the sequence repeats, the earlier and more severe the disease symptoms.

The disease-causing mutations involve repeats of the nucleotides guanine and cytosine, specifically repeats of GGGGCC segments on chromosome 9, open reading frame 72. The number of disease-causing repeats can range from around 60 into the thousands. People who inherit the diseased gene can develop ALS, FTD or both. Studies have estimated that around 1 in 5 people diagnosed with familial ALS, and around 1 in 10 people with familial FTD carry the C9 mutations. The average age of symptom onset is 58.

This is a disease that runs in families. Based on the number of repeats, doctors can assess whether a patient would be affected with the disease. So, you know before a patient has symptoms that they have a high likelihood of developing it, and yet there is no treatment, Disney says. That makes it even more imperative to develop strategies to that could create a medicine.

A team effort

To assess the effectiveness of their compounds, the team needed both diagnostic biomarkers and patient-derived neurons displaying the C9 mutations. The Petrucelli group at Mayo Clinic has extensively studied C9 ALS/FTD and developed the diagnostic biomarkers. The Rothstein group at Johns Hopkins treats and researches ALS and provided stem cells, which the Disney Lab then brought forward into neurons that displayed the diseased array of GGGGCC repeats.

In their research, Disneys team designed a compound that targeted the RNA involved in transcribingthe gene causing the disease. The compound causes an interaction between the RNA and pathways that a cell uses to eliminate RNAs. The compound eliminated 70 percent of the toxic protein fragments from mice bread to have the disease, and removed most hallmarks of the disease from the patient-derived nerve cells.

A single injection in the mice showed benefit through the entire length of the study period, which was six weeks, says Jessica Bush, a graduate student at Scripps Research's Skaggs Institute for Chemical Biology, who was the papers first author.

I think that its so exciting that we can look at a disease like ALS, and by taking a different approach or new perspective, we can open the door to a whole new world of possibilities, and start down the road toward therapies, Bush says.

Basic science behind the discovery

Disney designed the compound by applying nearly 15 years of his groups research on finding druggable structures on RNA, a notoriously changeable and transient molecule, and building a library of compounds able to bind those druggable structures.

The successful compound works by binding tightly to the disease-causing RNA in multiple places, while also attracting an enzyme that eliminates RNAs. Nature apparently created the degrading enzyme to defend cells from viral infection and provide quality control for protein production.

We co-opt a natural process to eliminate disease-causing RNA, Disney says. A full analysis of the RNAs in the cells treated with the compound showed it was very specific and selective.

Moving the technology forward to where it can be tested in humans requires a large amount of additional tests and refinements, a process that may take several years, Disney adds.

These studies, we hope, will advance new ways of targeting the RNA that causes ALS as well as other diseases, he says. There is a possibility here to eventually treat these patients before they develop symptoms, but it will be a long road before reaching the clinic.

Science Translational Medicine

Experimental study

Animals

Ribonuclease recruitment using a small molecule reduced c9ALS/FTD r(G4C2) repeat expansion in vitro and in vivo ALS models

27-Oct-2021

M.D.D. is a founder of Expansion Therapeutics. M.D.D. is a consultant for Expansion Therapeutics, and E.T.W. was a consultant for Expansion Therapeutics during the course of these studies. A patent disclosure has been filed on aspects of this work.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read the rest here:
ALS and dementia attacked by an RNA-hunting compound that recruits cell's own virus fighter - EurekAlert

Last Price$ Last TradeChange$ Change Percent %Open$ Prev Close$ High$ low$ 52 Week High$ 52 Week Low$ Market CapPE RatioVolumeExchange

BCLI - Market Data & News

Today, Brainstorm Cell Therapeutics, Inc. Incs (NASDAQ: BCLI) stock fell $0.02, accounting for a 0.65% decrease. Brainstorm Cell, opened at $3.05 before trading between $3.10 and $2.94 throughout Mondays session. The activity saw Brainstorm Cell,s market cap fall to $111,134,797 on 229,375 shares -above their 30-day average of 90,730.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm is also conducting an FDA-approved Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed dosing in December 2020, and topline results are expected by the end of the first quarter 2021.

Visit Brainstorm Cell Therapeutics, Inc.'s profile for more information.

Here's a trending selection from our newsletter, The Daily Fix, that captured readers' attention.Click hereto subscribe and get The Daily Fix delivered right to your inbox.

Restaurant Brands International Misses Revenue Estimates; Cites Staffing Shortage, COVID-19

Burger King and Tim Hortons are struggling with a staffing crunch and the Delta variant keeping coffee-loving office workers at home, causing parent Restaurant Brands International Inc (NYSE: QSR), to miss estimates for quarterly revenue on Monday.

U.S.-listed shares shed 4.4% as same-store sales at its Burger King, Tim Hortons and Popeyes chains came in below expectations in the third quarter.

[More]

Sustainable Shoe Maker Allbirds Seeks IPO Valuation North of $2 Billion

Sustainable shoe brand Allbirds Inc is eyeing a valuation exceeding $2 billion in its US initial public offering (IPO).

In its amended Form S-1 filed Monday, the company said it is offering about 19.23 million shares priced between $12 and $14 apiece. At the high end of that range, Allbirds would fetch gross proceeds of over $269 million.

[More]

Hertz Orders 100,000 Tesla Model 3 Vehicles; First Step Toward Electrifying Fleet

Hertz Global Holdings Inc (OTC: HTZZ) has placed an order for 100,000 Tesla Inc (NASDAQ: TSLA) electric cars, the first step in the rental car companys plan to electrify its fleet of a half million cars.

Starting in early November, the Florida-based company will offer Tesla Model 3 compact cars for rent at its airport and neighborhood locations in major US markets and certain European cities, Hertz announced Monday.

[More]

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Brainstorm Cell Therapeutics, Inc. and to follow the company's latest updates, you can visit the company's profile page here: Brainstorm Cell Therapeutics, Inc.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE:The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Continued here:
Brainstorm Cell, (BCLI) falls 0.65% in Active Trading on October 25 - Equities.com

The latest study on TheGlobal Mesenchymal Stem Cells Market 2021helps companies increase a competitive advantage in the industry by examining serious factors for market expansion. It explains the main global developments, dominant strategies, and perspectives in order to design effective business plans. The Mesenchymal Stem Cells Market research provides detailed market development prospects, an overview of market size and value, and current business trends. This research examined several elements of the demand for Mesenchymal Stem Cells. This study report goes into detail about the many factors that have contributed to the growth of the Mesenchymal Stem Cells market. In order to forecast and determine the global market size, bottom-up and top-down techniques are used.

Get Sample PDF Report of Exploration Report: https://www.qyreports.com/request-sample/?report-id=321253

Major Market Players Profiled in the Report include:

Lonza, Thermo Fisher, Bio-Techne, ATCC, MilliporeSigma, PromoCell GmbH, Genlantis, Celprogen, Cell Applications, Cyagen Biosciences, Axol Bioscience

Report Coverage:

The research study of the Mesenchymal Stem Cells market covers Introduction, product scope, market outline, market openings, market hazard, significant market-main thrust alongside the top makers and examinations their business, sales, and value choices for the term 2021 and 2028. Also, the report presents the cutthroat idea of the market by talking about the opposition among the main makers. The report inquiries the market with the assistance of deals, income, and share information for 2021 and 2028.

Additionally, the income and share of the worldwide Mesenchymal Stem Cells market for the audit time surround 2021-2028 are remembered for the report. The detailed examination of the significant geographic alongside deals, sales and portion of the overall industry by key nations in these locales are remembered for the report. Further, the report discusses the market division, for example, application and kinds of Mesenchymal Stem Cells market applying a similar organization of information for the time of 2021-2028. The market figure by districts, types, and applications utilizing deals and sales data for the projected time frame 2021-2028.

Ask for Discount: https://www.qyreports.com/ask-for-discount/?report-id=321253

Market by Type:

Market by Application:

Regional analysis for the global Mesenchymal Stem Cells market:

North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe), Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia), South America (Brazil, Argentina, Colombia, and Rest of South America), Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

Crucial pointers from the Mesenchymal Stem Cells Market report:

Fill the Pre-Order Enquiry form for the report: https://www.qyreports.com/enquiry-before-buying/?report-id=321253

In the end the Global Mesenchymal Stem Cells Market Report delivers conclusion which includes Research Findings, Market Size Estimation, Market Share, Consumer Needs/Customer Preference Change and Data Source. These factors will increase business overall.

Note: If you have any special requirement, please let us know and we will offer you the report as you want.

Contact Us:

Name: Jones John

Contact number: +1-510-560-6005

204, Professional Center,

7950 NW 53rd Street, Miami, Florida 33166

sales@qyreports.com

http://www.qyreports.com

Read more:
Global Mesenchymal Stem Cells Market Prospects, Upcoming Trends and Competitive Outlook till 2028 | Lonza, Thermo Fisher, Bio-Techne, ATCC,...

Published: Oct. 4, 2021 at 4:02 PM EDT

ORLANDO, Fla., Oct. 4, 2021 /PRNewswire/ --Billions of dollars are spent every year because of complications of wound healing. Researchers at the College of Medicine at the University of Central Florida (UCF) in Orlando have discovered a new technology to accelerate wound healing. Their research is published in the Life Cell Biology and Tissue Engineering Journal (https://pubmed.ncbi.nlm.nih.gov/34575027/). The UCF lab's research focus is to develop stem cell therapies for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, wound healing and ALS.

Researchers at the College of Medicine at UCF in Orlando have discovered a new technology to accelerate wound healing.

Dr. Frederick R Carrick, Professor of Neurology at the College of Medicine at UCF, reported that animals with wounds and injured stem cells that were placed on a special ceramic blanket healed much faster than controls. Gladiator Therapeutics manufactured the therapeutic ceramic blanket that was used in this research. The researchers reported that wounds in animals and in stem cells were both repaired significantly faster when they treated them with the ceramic blankets.

This research was designed and accepted for presentation at the USA Department of Defense's premier scientific meeting, the Military Health System Research Symposium (MHSRS). Dr Carrick stated that the new ceramic blankets do not need a power supply and are ideally suited for use in both combat and civilian wound treatments. Large wounds, such as those suffered in combat are easily infected and may result in increased suffering, disability and death amongst Warfighters. Faster healing of wounds can decrease pain and suffering and save lives.

The UCF College of Medicine research team is conducting ongoing research on the use of the Gladiator ceramic blanket in animal models of Alzheimer's and Parkinson's disease, traumatic brain injury and wound care. They have recently developed a new Alzheimer's therapy combining drugs that affect stem cells that increase the development of brain cells and improve brain function. The UCF lab is also the first to transplant stem cells isolated from the human brain to aged rats where they showed increased development of new brain cells and improvement of cognition.

Dr. Kiminobu Sugaya, Professor of Medicine at the UCF College of Medicine is excited about their findings. Dr. Sugaya stated that the benefits of using the Gladiator ceramic blanket are that it can be used anywhere without a power supply or the side effects that are commonly found when injecting chemicals or drugs.

Further information about this study:

drfrcarrick@post.harvard.edu 321-868-6464

View original content to download multimedia:

SOURCE University of Central Florida College of Medicine

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

See more here:
Faster healing of wounds can decrease pain and suffering and save lives - WWNY